Results 51 to 60 of about 1,267,582 (207)

Use of buprenorphine/naloxone combination for the treatment of opioid dependence: Antalya sample

open access: yesPsychiatry and Clinical Psychopharmacology, 2021
Objective: In this study, retrospective investigation of the effects of the sociodemographic attributes in opiate dependents on Buprenorphine/Naloxone combination and symptomatic medication treatments is aimed.
F Mükerrem Güven   +3 more
doaj  

The association between nicotine dependence and physical health among people receiving injectable diacetylmorphine or hydromorphone for the treatment of chronic opioid use disorder

open access: yesAddictive Behaviors Reports, 2018
Introduction: People with chronic opioid use disorder often present to treatment with individual and structural vulnerabilities and remain at risk of reporting adverse health outcomes.
Heather Palis   +12 more
doaj   +1 more source

Innovative Approach Reveals How Receptors Control G Protein State Equilibria

open access: yesAdvanced Science, EarlyView.
Using conformational specific trFRET biosensors of the Gi protein (depicted at the bottom), the authors show that receptor activation can not only release GDP from the inactive G protein, but can also release GTP from the activated G protein, leading to the reformation of the RG ternary complex.
Alexandre Bouyssou   +12 more
wiley   +1 more source

Lack of association between the A118G polymorphism of the mu opioid receptor gene (OPRM1) and opioid  dependence: A meta-analysis

open access: yesPharmacogenomics and Personalized Medicine, 2009
Janet K Coller1, Julia Beardsley1, James Bignold1, Yibai Li1, Florence Merg1, et al1Discipline of Pharmacology, School of Medical Sciences; 2Discipline of Public Health, School of Population Health and Clinical Practice; 3School of Biomedical and ...
Janet K Coller   +5 more
doaj  

qcGEM: A Graph‐Based Molecular Representation With Quantum Chemistry Awareness

open access: yesAdvanced Science, EarlyView.
In this work, we introduce qcGEM, a quantum‐chemistry‐aware graph‐based embedding of molecules that incorporates physical priors into molecular representation learning. Through a specially designed model architecture to adequately process quantum chemistry information as well as three‐dimensional molecular geometry, qcGEM provides a compact, physics ...
Haoyu Wang   +3 more
wiley   +1 more source

Contemporary management of pain in cirrhosis: Toward precision therapy for pain

open access: yesHepatology, EarlyView., 2022
Abstract Chronic pain is highly prevalent in patients with cirrhosis and is associated with poor health‐related quality of life and poor functional status. However, there is limited guidance on appropriate pain management in this population, and pharmacologic treatment can be harmful, leading to adverse outcomes, such as gastrointestinal bleeding ...
Alexis Holman   +4 more
wiley   +1 more source

Stabilization of remission in patients with opioid depen dence: pharmacological and pharmacogenetic aspects

open access: yesУчёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова, 2016
Modern narcology demonstrates a problem of insufficient effectiveness of pharmacotherapy for stabilization of remission in patients with opioid dependence.
V. Ya. Palatkin   +4 more
doaj   +1 more source

EphB1 Receptor Blockade Augments Morphine Antinociception via Inhibiting GRK2‐Mediated µ‐Opioid Receptor Internalization

open access: yesAdvanced Science, EarlyView.
Administration of opioids activates ephrinB2‐EphB1 receptor signaling. Activated EphB1 receptors induce GRK2‐mediated phosphorylation of MOR at Ser375, which initiates the internalization of MOR and reduces opioid antinociception at the behavioral level. ABSTRACT Opioids are the primary treatment for severe pain in clinical practice.
Bo Peng   +7 more
wiley   +1 more source

Stress-evoked opioid release inhibits pain in major depressive disorder [PDF]

open access: yes, 2008
To determine whether stress-evoked release of endogenous opioids might account for hypoalgesia in major depressive disorder (MDD), the μ-opioid antagonist naltrexone (50 mg) or placebo was administered double-blind to 24 participants with MDD and to 31 ...
Frew, A.K., Drummond, P.D.
core  

Buprenorphine in the treatment of opioid dependence

open access: yes, 2007
Methadone has been the mainstay of pharmacological management of opioid dependence since the 1960s but buprenorphine is fast gaining acceptance among addiction specialists and patients. This article provides an overview of buprenorphine, its pharmacology,
Day, Edward; id_orcid, George, S
core   +4 more sources

Home - About - Disclaimer - Privacy